Pipeline
Home » Pipeline » Zolpimist™
Pipeline NitroMist Zensana NVD-201 NVD-401 NVD-501 NVD-301

Zolpimist™
Zolpimist™ (zolpidem oral spray) uses NovaDel’s proprietary formulation technology to deliver zolpidem tartrate, which is currently marketed as Ambien®, the leading hypnotic for the treatment of insomnia.  NovaDel has announced positive results from its clinical studies comparing zolpidem oral spray with Ambien® tablets.  Zolpimist™ has been approved by the FDA for the short-term treatment of insomnia characterized by difficulties with sleep initiation.

Zolpimist™ offers the potential benefit of a faster rise in drug blood levels potentially leading to a faster onset of action, without having to take water.


Clinical Studies

The Company has completed three clinical studies comparing Zolpimist™ to Ambien® tablets.  The two pivotal studies are described below:

NVD003  – Healthy volunteers with mean age of 29 years
Study NVD003 compared 5 mg and 10 mg doses of Zolpimist™ with comparable doses of Ambien® tablets.  Pursuant to FDA guidance in this type of 4-way crossover study, all data were compared to the highest marketed dose, which in this study was the 10 mg Ambien® tablet.  Positive results from the study demonstrated that NovaDel’s 10 mg and 5 mg Zolpimist™ achieved bioequivalence with 10 mg Ambien® tablets, the primary standard of reference for this study.

A secondary assessment of the relationship between speed of drug absorption and the attainment of  therapeutic drug levels showed 79% of subjects using the 10 mg Zolpimist™ reached therapeutic levels at 15 minutes post-dosing while only 26% of subjects using 10 mg tablets reached therapeutic levels at that time point. The results were statistically significant.

NVD004 – Healthy, elderly volunteers with mean age of 71 years
Study NVD004 compared doses of 5 mg Zolpimist™ to 5 mg Ambien® tablets. The primary objective of the study was to demonstrate comparability/bioequivalence of pharmacokinetics between oral spray and tablet groups. 

A secondary assessment of the relationship between speed of drug absorption and the attainment of therapeutic drug levels showed 65% of subjects using the 5 mg Zolpimist™ reaching therapeutic levels at 15 minutes post-dosing while only 19% of subjects in the tablet group reached therapeutic levels by 15 minutes. The results were statistically significant.

Current Status

Zolpimist™ has been approved by the FDA for the short-term treatment of insomnia characterized by difficulties with sleep initiation.  NovaDel is seeking a partner for its commercialization.

Zolpimist™ for Middle-of-the-Night Awakenings (MOTN)

Clinical studies have demonstrated that a low dose of zolpidem is effective in treating a sub-set of insomnia patients who wake up during the night and have difficulty falling back asleep.  NovaDel has begun development of a lower dose version of Zolpimist™ with the intent of performing clinical trials to demonstrate the benefit of an easy-to-use oral spray form of zolpidem in this important and large patient population.

About Insomnia

Insomnia is a sleep disorder whose sufferers experience inadequate or poor quality sleep and report one or more of the following: difficulty initiating sleep, difficulty maintaining sleep, and waking up too early. According to the “2005 Sleep in America Poll,” 54% of those surveyed indicated they experience at least one symptom of insomnia a few nights per week. Approximately one third of insomniac suffer from middle-of-the-night awakenings.  Only approximately 14% of the respondents reported using any sort of sleep-aid therapy. Walsh and Engelhardt (1999) estimated $14 billion is spent each year on the direct costs of insomnia, including pharmaceuticals, healthcare services and hospital and nursing home care. Cowen & Company estimated the total non-benzodiazepine prescription market in the U.S. for the treatment of insomnia in 2007 was approximately $3.4 billion, growing to $3.8 billion by 2011. Ambien®/Ambien CR™ (zolpidem tartrate) are the dominant products with approximately 80% of the market in 2006. The patent on Ambien® has expired and generic products were recently introduced.